Activation of B-CLL cells by anti CD180 monoclonal antibodies: Responder and non-responder patients.

被引：0
|
作者：
Porakishvili, N
Slovick, A
Jewell, AP
Youinou, PY
Nathwani, A
Yong, K
Stevenson, F
Clark, EA
Lydyard, PM
机构：
[1] Univ Westminster, Sch Biosci, London, England
[2] Royal Free & UCL Med Sch, London, England
[3] Kingston Univ, Sch Life Sci, Kingston upon Thames KT1 2EE, Surrey, England
[4] Brest Univ, Brest, France
[5] Univ Southampton, Tenovus Res Labs, Southampton SO9 5NH, Hants, England
[6] Univ Washington, Seattle, WA 98195 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1571
引用
收藏
页码：432A / 432A
页数：1
相关论文
共 50 条
  • [11] Responsiveness to CD40 monoclonal antibodies and clinical stage of B-CLL
    Jacob, A
    Pound, JD
    Challa, A
    Gordon, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 45 - 45
  • [12] THE DEVELOPMENT OF NON-RESPONSIVENESS TO IMMUNOTHERAPY WITH MONOCLONAL ANTI-IDIOTYPIC ANTIBODIES IN A PATIENT WITH B-CLL
    ALLEBES, WA
    PREIJERS, FWMB
    HAANEN, C
    CAPEL, PJA
    BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (03) : 295 - 300
  • [13] AM3 administration appears to reverse the non-responder status to hepatitis B vaccination in haemodialysis (HD) patients.
    Jarillo, MD
    GarciaMartin, F
    Sada, G
    Calvo, CG
    Prieto, A
    Goni, M
    Villarubia, VG
    deMon, MA
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A2640 - A2640
  • [14] Activation and proliferation of B cell chronic lymphocytic leukaemia (B-CLL) cells through anti-CD180, Anti-CD40 and IL-4.
    Porakishvili, N
    Manoussaka, M
    Kulikova, N
    Walton, J
    Nathwani, A
    Jewell, AP
    Stevenson, F
    Clark, E
    Lydyard, PM
    BLOOD, 2004, 104 (11) : 277B - 277B
  • [15] THE EXPRESSED SPECIFICITY REPERTOIRE OF T-CELLS IS UNINFLUENCED BY NON-MHC GENES IN RESPONDER AND NON-RESPONDER H-2B MICE
    SADEGHNASSERI, S
    SHASTRI, N
    GAMMON, G
    SERCARZ, E
    FEDERATION PROCEEDINGS, 1985, 44 (04) : 968 - 968
  • [16] DCE-MRI DISCRIMINATES BETWEEN RESPONDER AND NON-RESPONDER IN PROGRESSIVE HIGH GRADE GLIOMA PATIENTS UNDERGOING ANTI-ANGIOGENIC TREATMENT
    Nowosielski, Martha
    Kremser, Christian
    Schocke, Michael
    Gizewski, Elke
    Iglseder, Sarah
    Muigg, Armin
    Freyschlag, Christian
    Stockhammer, Guenther
    Hutterer, Markus
    NEURO-ONCOLOGY, 2014, 16
  • [17] Different expression of CD180, CD284 and CD14 receptors on the CD19+ subpopulation of normal and B-CLL lymphocytes
    Antosz, Halina
    Sajewicz, Joanna
    Marzec-Kotarska, Barbara
    Kocki, Janusz
    Dmoszynska, Anna
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2009, 47 (04) : 593 - 598
  • [18] Constitutive activation of NFκB2 in a subset of B-CLL patients.
    Munzert, G
    Stobbe, H
    Schrem, S
    Kirchner, D
    Bergmann, L
    BLOOD, 1998, 92 (10) : 484A - 485A
  • [19] Soluble CD30 and CD26 levels in plasma help stratify methotrexate (MTX)-responder versus non-responder rheumatoid arthritis (RA) patients
    Marcelletti, JF
    Dervieux, T
    Lein, DO
    Smith, K
    Simpson, L
    Meyer, G
    Walsh, M
    Weisman, M
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S158 - S158
  • [20] Heterogeneity of expression of toll-like receptor RP105 (CD180) by B cell chronic lymphocytic leukaemic (B-CLL) cells.
    Porakishvili, N
    Kulikova, N
    Sundar, S
    Jewell, AP
    Youinou, PY
    Nedelec, S
    Yong, K
    Stevenson, F
    Hamblin, TJ
    Wallace, P
    Ely, P
    Clark, EA
    Lydyard, PM
    BLOOD, 2002, 100 (11) : 353B - 353B
12345